---
document_datetime: 2023-09-21 21:24:58
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/waylivra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: waylivra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.1468725
conversion_datetime: 2025-12-15 01:40:58.08146
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## WAYLIVRA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|----------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| IAIN/0023            | A.1 - Administrative change - Change in the name and/or address of the MAH | 08/11/2022                          |                                             | SmPC, Labelling and PL           |                                                                                                                        |
| II/0017/G            | This was an application for a group of variations.                         | 07/07/2022                          |                                             | SmPC, Labelling and              | Update of sections 4.8 and 5.1 of the SmPC to include data from final results of study ISIS 304801 CS7 ('a multicentre |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| C.I.4: Update of sections based on the final results CS7), a multicentre open Volanesorsen administered patients with Familial Chylomicronemia The Package Leaflet has The RMP version 2.2 has In addition, the MAH took implement editorial changes align with the QRD template linguistic update to Annex information to support C.I.11b. for RMP: Submission version 2.2 based on the addendum: A randomized, controlled Phase 3 study administered subcutaneously Familial Chylomicronemia CS6 (APPROACH). C.I.11b. for RMP: Submission version 2.2 in order to Risk Minimisation Measures change in the distribution educational materials (from localised model of distribution) meant by the prescriber C.I.13: Submission of the ISIS 304801 (CS17). This   | open label extension study of Volanesorsen administered subcutaneously to patients with Familial Chylomicronemia Syndrome'). The Package Leaflet and RMP have been   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | open label extension of ISIS 304801 administered subcutaneously to patients with familial partial lipodystrophy. The RMP version 2.2 has also been submitted. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10762 /202111 | Periodic Safety Update EU Single assessment - volanesorsen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/06/2022 | n/a | PRAC Recommendation - maintenance |
| IB/0020             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 31/03/2022 | n/a |                                   |
| IA/0019/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/03/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |                                  |                                                                                                                 |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------|
| R/0016              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/12/2021 | 14/02/2022 |                                  |                                                                                                                 |
| PSUSA/10762 /202105 | Periodic Safety Update EU Single assessment - volanesorsen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 02/12/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                               |
| IB/0015             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/10/2021 | 14/02/2022 | SmPC, Annex II, Labelling and PL |                                                                                                                 |
| IB/0014             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/09/2021 | n/a        |                                  |                                                                                                                 |
| PSUSA/10762 /202011 | Periodic Safety Update EU Single assessment - volanesorsen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 10/06/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                               |
| IB/0011/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/05/2021 | 14/02/2022 | SmPC, Labelling and              | The Product Information includes the following updates: - To include the ATC Code in Section 5.1 of the Summary |

<div style=\"page-break-after: always\"></div>

|                     | A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                          |            |            | PL   | Product Characteristics (SmPC). - To change the shelf-life from '4 years' to '5 years' in section 6.3 of the SmPC. - To introduce editorial changes throughout the product information.                                                                                                                                                                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0009              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/12/2020 | 04/02/2021 |      | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for WAYLIVRA, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10762 /202005 | Periodic Safety Update EU Single assessment - volanesorsen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/11/2020 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0008/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.d.1.c - Stability of AS - Change in the re-test | 12/10/2020 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                              | 12/06/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10762 /201911 | Periodic Safety Update EU Single assessment - volanesorsen                                                                                                                                                                          | 11/06/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0005             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                           | 24/04/2020 | 04/02/2021 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0003              | Renewal of the marketing authorisation.                                                                                                                                                                                             | 30/01/2020 | 16/03/2020 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for WAYLIVRA, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0002             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                              | 18/07/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IB/0001   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf   | 18/07/2019   | 16/03/2020   | SmPC   |
|-----------|-----------------------------------------------------------|--------------|--------------|--------|